Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3474 - Preselecting tumor-infiltrating lymphocyte subsets to implement adoptive inmmunotherapy in ovarian cancer


29 Sep 2019


Poster Display session 2


Tumour Site

Ovarian Cancer


Diego Salas-Benito


Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250


D. Salas-Benito1, C. De Andrea2, J.M. Aramendia3, U. Mancheño4, E. Elizalde4, E. Conde4, I. Tamayo4, F. Guillén1, M. Jurado5, J.Á. Mínguez5, A. González Martín6, M. Ponz-Sarvise7, S. Hervás-Stubbs4

Author affiliations

  • 1 Dept. Oncology, Clinica Universitaria de Navarra, 31008 - Pamplona/ES
  • 2 Pathology, Clínica Universidad de Navarra, 31008 - Pamplona/ES
  • 3 Medical Oncology, Clinica Universidad de Navarra, 31008 - Pamplona/ES
  • 4 Immunomodulatory Therapies, Center for Applied Medicine Research, 31008 - Pamplona/ES
  • 5 Gynaecology, Clínica Universidad de Navarra, 31008 - Pamplona/ES
  • 6 Medical Oncology Department, Clínica Universidad de Navarra, 28036 - Madrid/ES
  • 7 Clinical Oncology, Clínica Universidad de Navarra, 31008 - Pamplona/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3474


Adoptive cell therapy (ACT) of expanded in-vitro tumour specific T-cells isolated from fresh tumour infiltrates has shown promising results in melanoma patients, and in ovarian cancer (OC). The use of pre-enriched tumor-specific T cells may simplify the TIL production method and enhances the tumour-reactivity of the final cellular product. We have investigated the role of PD-1 as a biomarker for the isolation and expansion of tumour-specific CD8 TILs in OC.


Samples from ten OC patients were analyzed. We used flow cytometry FACs Aria sorter for phenotyping and separate T-cells. For reactivity assay we performed co-cultures of TILs with autologous tumour and non-related tumor cell line, and measured INFγ released by ELISPOT. For immunofluorescence multiplex we used a Vectra® microscope and inForm® software to analyzed data. Tumour DNA sequencing was done using a TrueShight™ 170 gene panel.


Both CD8+PD-1+and CD8+PD-1- TIL subsets expanded efficiently and no difference in fold expansion was found. Tumor-reactive TILs were detected in 5/10 patients and this tumor-reactivity was exclusively present in the cells derived from the PD-1+-enriched fraction. There were a higher frequency of CD8+PD-1+CD137+ by FC (p = 0,0079) in reactive group in fresh biopsy. Total CD8+and CD8+PD-1+were more frequent in reactive patients (p = 0,0079, p = 0,0317). CD8+PD-1+CD137+were more frequent (p = 0,0437) by IF in the tumoral epithelium of reactive patients. There were more total CD4+ and CD4+PD-1+by FC in reactive group (p = 0,0079, p = 0,0159). By IF we observed more CD4+PD-1+in both epithelium and stroma of reactive group (p = 0,0437). Patients with reactive TILs exhibited significantly high number of missense mutactions (p = 0,0198).


CD8+PD-1+ T-cell subset include tumour-specific T-cell in OC. CD8+PD-1+CD137+ cells in epithelium may work as a biomarker for reactivity. Higher mutation load is related with tumour-reactive TILs in OC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


ISCIII Spanish grant (PI15/02027).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.